Exscientia (EXAI)
(Delayed Data from NSDQ)
$5.28 USD
-0.03 (-0.56%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $5.30 +0.02 (0.38%) 6:32 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$5.28 USD
-0.03 (-0.56%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $5.30 +0.02 (0.38%) 6:32 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Zacks News
Wall Street Analysts Think Exscientia PLC Sponsored ADR (EXAI) Could Surge 63%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 62.6% in Exscientia PLC Sponsored ADR (EXAI). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Evotec (EVO) Inks Drug Discovery Collaboration Deal With J&J
by Zacks Equity Research
Evotec (EVO) signs a collaboration agreement with Janssen, a wholly owned subsidiary of J&J, for discovering novel drugs in the field of protein homeostasis. Shares down.
Exscientia PLC Sponsored ADR (EXAI) Upgraded to Buy: Here's Why
by Zacks Equity Research
Exscientia PLC Sponsored ADR (EXAI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Esperion (ESPR) Q1 Earnings Beat on Robust Demand for Drugs
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports solid first-quarter results, beating estimates for earnings and sales. Cost-savings programs boost margins. Stock rallies.
Is Exscientia PLC Sponsored ADR (EXAI) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Exscientia PLC Sponsored ADR (EXAI) and Henry Schein (HSIC) have performed compared to their sector so far this year.
Sanofi (SNY) Inks Deal to Develop AI-Driven Precision Medicines
by Zacks Equity Research
Sanofi (SNY) signs a collaboration agreement with Exscientia to develop precision-engineered medicines in oncology and immunology using the latter's AI-driven platform.